Wikisage, the free encyclopedia of the second generation, is digital heritage

Belzutifan

From Wikisage
Revision as of 23:42, 13 August 2021 by Penarc (talk | contribs) (ATC)
Jump to navigation Jump to search

Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).

Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)[1]

ATC

none

Belzutifan.png
belzutifan

Buecher Regal 636.jpg Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs[2]

External links

[Ben-Skowronek I, Kozaczuk S] 2015: Von Hippel-Lindau Syndrome. Horm Res Paediatr 84:145-152. doi: 10.1159/000431323

Q27456641 op Wikidata  Interwiki via Wikidata


References

References: